Literature DB >> 20367081

The role of carrier size in the pharmacodynamics of antisense and siRNA oligonucleotides.

Leaf Huang1, Bruce Sullenger, Rudy Juliano.   

Abstract

Effective therapeutic utilization of antisense and siRNA oligonucleotides represents a major challenge to drug delivery science. Although many strategies and technologies have been applied to oligonucleotide delivery, a key issue remains the role of molecular or carrier size. In this brief review, we address some of the size-related parameters that regulate the biodistribution of oligonucleotides. We also reprise several recent studies that have examined the inter-relationship of size and shape in influencing delivery.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20367081     DOI: 10.3109/10611861003734019

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  8 in total

1.  Porphysome nanovesicles generated by porphyrin bilayers for use as multimodal biophotonic contrast agents.

Authors:  Jonathan F Lovell; Cheng S Jin; Elizabeth Huynh; Honglin Jin; Chulhong Kim; John L Rubinstein; Warren C W Chan; Weiguo Cao; Lihong V Wang; Gang Zheng
Journal:  Nat Mater       Date:  2011-03-20       Impact factor: 43.841

2.  RGD-Modified Albumin Nanoconjugates for Targeted Delivery of a Porphyrin Photosensitizer.

Authors:  Fang Li; Yan Zhao; Chengqiong Mao; Yi Kong; Xin Ming
Journal:  Mol Pharm       Date:  2017-07-25       Impact factor: 4.939

3.  Regulation of inflammatory arthritis by the upstream kinase mitogen activated protein kinase kinase 7 in the c-Jun N-terminal kinase pathway.

Authors:  Sang-il Lee; David L Boyle; Andres Berdeja; Gary S Firestein
Journal:  Arthritis Res Ther       Date:  2012-02-21       Impact factor: 5.156

4.  Albumin-based nanoconjugates for targeted delivery of therapeutic oligonucleotides.

Authors:  Xin Ming; Kyle Carver; Lin Wu
Journal:  Biomaterials       Date:  2013-07-19       Impact factor: 12.479

5.  Microfluidic Synthesis of Highly Potent Limit-size Lipid Nanoparticles for In Vivo Delivery of siRNA.

Authors:  Nathan M Belliveau; Jens Huft; Paulo Jc Lin; Sam Chen; Alex Kk Leung; Timothy J Leaver; Andre W Wild; Justin B Lee; Robert J Taylor; Ying K Tam; Carl L Hansen; Pieter R Cullis
Journal:  Mol Ther Nucleic Acids       Date:  2012-08-14       Impact factor: 10.183

Review 6.  Nanoparticle-mediated systemic delivery of siRNA for treatment of cancers and viral infections.

Authors:  Mohamed Shehata Draz; Binbin Amanda Fang; Pengfei Zhang; Zhi Hu; Shenda Gu; Kevin C Weng; Joe W Gray; Fanqing Frank Chen
Journal:  Theranostics       Date:  2014-06-11       Impact factor: 11.556

7.  Co-delivery of paclitaxel and anti-VEGF siRNA by tripeptide lipid nanoparticle to enhance the anti-tumor activity for lung cancer therapy.

Authors:  Chuanmin Zhang; Yinan Zhao; Enxia Zhang; Meilin Jiang; Defu Zhi; Huiying Chen; Shaohui Cui; Yuhong Zhen; Jingnan Cui; Shubiao Zhang
Journal:  Drug Deliv       Date:  2020-12       Impact factor: 6.419

8.  Biodistribution and Pharmacokinetics Study of siRNA-loaded Anti-NTSR1-mAb-functionalized Novel Hybrid Nanoparticles in a Metastatic Orthotopic Murine Lung Cancer Model.

Authors:  Maryna Perepelyuk; Chellappagounder Thangavel; Yi Liu; Robert B Den; Bo Lu; Adam E Snook; Sunday A Shoyele
Journal:  Mol Ther Nucleic Acids       Date:  2016-01-26       Impact factor: 10.183

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.